A little more than four years ago, longtime friends Tom and Carman Duvall, and Kiers and Steve Rowley reminisced at dinner about their lives in the 1980s, long before their schedules had grown complicated and filled with endless trips driving children to various activities.
Tom, a child of 1980s rock and roll, wondered aloud whether Def Leppard might perform for them on his next birthday. Conversation meandered during the evening, and when the check arrived, Tom and Steve advised Kiers and Carman that a date had been set for a rock concert on the Duvall property in Independence, Missouri, and that it would be a fundraising event to support patients suffering with cancer. Kiers, who’d struggled with lung cancer for the past five years, and Carman announced “We’re in.” So began an all-day-long summer music festival and tradition resembling Woodstock, that the four friends named Tomstock. Continue reading…
Last week, Cancer Commons founder Marty Tenenbaum spoke at the Precision Medicine World Conference (PMWC) in Durham, NC. He presented a proposal to significantly accelerate patient access to promising investigational drugs, using a new pathway to approval by the U.S. Food and Drug Administration (FDA).
The proposed Conditional Approval pathway aims to help cancer patients who may have exhausted existing options access new, promising treatments.
“It’s an idea whose time has come, and the conference provided strong validation, including some personal communications from several prominent FDA officials (past and present) who were in attendance,” Marty says. “We are currently in discussions with the FDA, and hope to be able to pilot Conditional Approval in brain cancer where the prognosis is dire.”
Cancer Commons founder Marty Tenenbaum, Ph.D., will speak at the upcoming Precision Medicine World Conference (PMWC) in Durham, NC, which runs May 24–25. Marty, who founded Cancer Commons after his own battle with melanoma, will discuss the organization’s ongoing efforts to address challenges to knowledge-sharing in precision oncology.
Read the synopsis of Marty’s presentation, entitled “Is An Additional Path to FDA Approval Possible?”:
This talk will explore the question: When faced with certain death, it is acceptable to accept less than 100% proven safety and efficacy?Patients with glioblastoma and certain other cancers with dire prognoses do not have the time to wait for new treatments to be fully approved by the FDA. Is it time to add “conditional approval” as an additional pathway to approval for these patients? In this session, a plan will be proposed by which the FDA could conditionally approve a treatment that has been proven safe in a clinical trial(s) with at least 25 patients, and has demonstrated biologic activity. Therefore, this treatment could not be denied by insurance as being “experimental”. However, the requires patients using these drugs to participate in a registry through which their physicians submit details on the treatments, side effects and outcomes. The FDA’s periodic review of the registry data would lead to a range of outcomes from full approval to the conditional approval being revoked.
Marty’s talk takes place on May 24 at 2:45 pm. For more information, visit the PMWC website.
Oncologist and Cancer Commons Medical Director Kevin Knopf, MD, will speak next month at TiEcon 2017, a technology conference in Santa Clara, CA. He’ll join three other experts to discuss the future of personalized medicine. From the program:
A new era of personalized medicine has made its way into the world of healthcare. We will discuss novel approaches for designing disease treatment and prevention that integrates with an individual’s genetic profile, environment and lifestyle.The future is here — let’s hear from industry luminaries on how digital health entrepreneurs and the healthcare industry as a whole are preparing for massive disruption.
Kevin’s presentation will take place on May 5 at 3:00 pm. For more information, visit the TiEcon website.
Update 3-1-17: A video of this event has now been released. Watch it below.
This year’s Precision Medicine World Conference in Mountain View, California, was well-attended by many members of Cancer Commons, who shared in the scientific discoveries that will lead the way to more personalized, accurate, and effective cancer care. Precision medicine is a rapidly evolving field with many breakthroughs in science, technology, and diagnosis that is transforming the way cancer care is practiced at the bedside.
A special session was co-chaired by Cancer Commons board member Larry Marton and Lincoln Nadauld, director of the personalized oncology program at Intermountain Healthcare in Utah. The session also featured Cancer Commons medical director Kevin Knopf, Mountain View oncologist Edmund Tai, and Tim Collins, who is corporate vice president of operations and research at Scripps Health in San Diego. Continue reading…
On May 21, HackCancer held its 4th Annual White Party in San Francisco. 100% of the net proceeds go to Cancer Commons and will help us get the right treatments to the right patients at the right time. A huge thank you to the organizers and to all who attended!
Above: Dominique Kim and Toni Alejandria show their support at the HackCancer White Party. See more photos of the event on our Facebook page.
We’re thrilled to announce that South by Southwest (SXSW) has named Cancer Commons founder Marty Tenenbaum a 2016 Dewey Winburne Community Service Award Honoree. Marty joins nine other remarkable honorees, all of whom use digital technology to help others. They were selected based on their qualities of “community, compassion, care, education and positive energy.”
Marty—along with the other awardees—will share his story on March 13, 2016 in Austin, TX.
Cancer Commons founder Marty Tenenbaum spoke last weekend at Medicine X, Stanford University’s conference for new ideas in medicine and healthcare. He told the story of his personal melanoma fight, and how difficult it was to find the information he needed to beat his cancer. This experience led him to found Cancer Commons, with the goal of developing a rapid learning platform to help patients explore their options and make the best, most personalized decisions about their cancer care.
The Shine Project and Cancer Commons invite you to join us for a night of music, dancing, and community. We’re celebrating the lives of those who have passed due to cancer, and the lives that we’re still living. All proceeds will enable Cancer Commons to help patients navigate their treatment.
When: Friday, October 23, 2015, 7:00 PM PST
Where: Fox Theatre Redwood City, CA